Hodgkin lymphoma with diplopia and nystagmus: a paraneoplastic cerebellar degeneration with ectopic expression of DNER antigen on Reed-Sternberg cells
Paraneoplastic neurological syndromes (PNSs) are heterogeneous and rare disorders (less than 1% of all neoplastic conditions) associated with various type of neoplasms, including both non-Hodgkin's lymphomas (NHLs) and Hodgkin's lymphoma (HL).1 –3 The primary cause is recognized in the aberrant immunological response against nervous tissue usually triggered by ectopic expression of so-called onco-neural antigens on neoplastic cells.2,4,5 This mechanism can be highlighted by the occurrence of onconeural antibodies which represent a powerf ul diagnostic tool, according to Graus and colleagues’ criteria. (Source: ...
Source: Clinical Lymphoma, Myeloma and Leukemia - October 20, 2021 Category: Hematology Authors: Nicolas Fiorelli, Sara Fraticelli, Arturo Bonometti, Luca Diamanti, Matteo Paoletti, Diego Franciotta, Manuel Gotti, Marco Lucioni, Marco Paulli, Luca Arcaini Tags: Case Report Source Type: research

A comparison of the clinical outcomes of haploidentical transplantation and other graft sources in acute lymphoblastic leukemia: a systematic review and meta-analysis
: Most likely due to the availability of potential stem cell sources, there appears to be a growing usage of haploidentical (haplo) donors for cases of acute lymphoblastic leukemia involving high-risk features or relapse. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 20, 2021 Category: Hematology Authors: Weerapat Owattanapanich, Nattawut Leelakanok, Kleebsabai Sanpakit, Jassada Buaboonnam Source Type: research

Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma
Immunoparesis is associated with poor survival in myeloma (MM). We demonstrate that the etiological cytogenetic abnormality influences the degree and clinical impact of immunoparesis in newly diagnosed patients in a large clinical trial. As the depth of IgM immunoparesis impacts survival for hyperdiploid patients, this may be used to further risk-stratify this cytogenetic subgroup of patients for future clinical decisions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 18, 2021 Category: Hematology Authors: Jessica Caro, David Cairns, Tom Menzies, Eileen Boyle, Charlotte Pawlyn, Gordon Cook, Martin Kaiser, Brian A Walker, Roger Owen, Graham H Jackson, Gareth J Morgan, Jennifer Heaney, Mark T Drayson, Faith E Davies Source Type: research

Safety of the anti-CD19 antibody Tafasitamab in long term responders from a phase II trial for relapsed lymphoma
Tafasitamab is a humanized Fc-modified cytolytic monoclonal antibody targeting CD19, which is expressed on most B-NHL, and is currently evaluated in relapsed or refractory lymphoma. Still little is known about its long-term effects. We evaluated long-term tolerability and toxicity in 5 patients with ongoing single-agent treatment for up to 5 years or longer, enrolled in a phase IIa trial. Responding patients could be treated until progression. Prolonged treatment was very well tolerated with only few adverse events (AEs) occurring mainly within the first 2 years, commonly infections (45%) and neurological symptoms (14%). (...
Source: Clinical Lymphoma, Myeloma and Leukemia - October 16, 2021 Category: Hematology Authors: Marie-Kristin Tilch, Tadeusz Robak, Chiara Ghiggi, Elke Wuff, Stephanie Herold, Matthias Theobald, Georg Hess Source Type: research

Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience
We report on 121 cases from major centers in North America. The majority of patients present with early stage disease, and CMT appears to provide optimal outcomes for appropriate candidates. Patients did poorly overall, regardless of race/ethnicity, highlighting need for further advances in the field. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 16, 2021 Category: Hematology Authors: Nora N. Bennani, Aung M. Tun, Kenneth R Carson, Jessica L Geiger, Lauren S Maeda, Kerry J Savage, Jim Rose, Lauren Pinter-Brown, Matthew A Lunning, Jeremy S Abramson, Nancy L Bartlett, Julie M Vose, Andrew M Evens, Sonali M Smith, Steven M Horwitz, Stephe Source Type: research

CAR-T in B-cell lymphomas: the past, present and future
The advent of chimeric antigen receptor T-cell therapy (CAR-T) is a historic landmark in the treatment of B-cell lymphoid malignancies considering its proven efficacy in the salvage setting for patients with limited effective therapeutic options. CAR-T cell therapy is also the first gene therapy to be approved by the US Food and Drug Administration (FDA) for clinical use, initially in B-cell acute lymphocytic leukemia and then shortly after in aggressive mature B-cell lymphomas1. In the case of aggressive mature B-cell lymphomas before CAR-T era, the retrospective international SCHOLAR-1 study demonstrated that the median ...
Source: Clinical Lymphoma, Myeloma and Leukemia - October 14, 2021 Category: Hematology Authors: Taha Al-Juhaishi, Sairah Ahmed Source Type: research

SOHO State of the Art Updates and Next Questions:"SOHO State of the Art Updates and Next Questions: Pathology and Pathogenesis of Nodal Peripheral T-Cell Lymphomas
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous and often clinically aggressive group of neoplasms derived from mature post-thymic T-lymphocytes. These neoplasms are rare and usually diagnostically challenging. Our understanding of the pathogenesis of PTCL is increasing and this improved knowledge is leading us to better molecular characterization, more objective and accurate diagnostic criteria, more effective risk assessment, and potentially better treatments. The focus of this paper is to present a brief overview of the current pathology criteria and molecular and genetic features of nodal peripheral T-cell lymp...
Source: Clinical Lymphoma, Myeloma and Leukemia - October 14, 2021 Category: Hematology Authors: Lianqun Qiu, Jeong Hee Cho, Fatima Zahra Jelloul, Francisco Vega Source Type: research

SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis
Myeloproliferative neoplasms (MPN) research has entered a dynamic and exciting era as we witness exponential growth of novel agents in advanced/early phase clinical trials for myelofibrosis (MF). Building on the success and pivotal role of ruxolitinib, many novel agents, spanning a wide range of mechanisms/targets (epigenetic regulation, apoptotic/intracellular signaling pathways, telomerase, BM fibrosis) are in clinical development; several are in registrational trials and hold great potential to expand the therapeutic arsenal/shift the treatment paradigm if regulatory approval is granted. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 12, 2021 Category: Hematology Authors: Helen T. Chifotides, Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Srdan Verstovsek Tags: Review Article Source Type: research

Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia with IDH Mutations: A Single Center Experience
Acute myeloid leukemia (AML) is a malignant process that is driven by cumulative genetic alterations that confer selective clonal advantage through maturation arrest and clonal proliferation. Among the most common genetic alterations in AML are mutations in the genes encoding isocitrate dehydrogenase (IDH) 1 and 2 enzymes, which are present in approximately 20% of AMLs.1 IDH1 and IDH2, cytosolic and mitochondrial isoforms, respectively, are key enzymatic components of the citric acid cycle, converting isocitrate to α-ketoglutarate. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 9, 2021 Category: Hematology Authors: Alexander Ambinder, Matthew Smith, Hua-Ling Tsai, Ravi Varadhan, Amy DeZern, William Dalton, Christian Gocke, Jonathan Webster, Lukasz Gondek, Ivana Gojo, Syed Abbas Ali, Carol Ann Huff, Lode Swinnen, Nina Wagner-Johnston, Margaret Showel, Gabrielle Princ Source Type: research

Oral azacitidine (CC-486) for the treatment of myeloid malignancies
Epigenetic dysregulation leads to aberrant DNA hypermethylation and is common in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). A large number of clinical trials in AML, MDS, and other hematologic malignancies have assessed hypomethylating agents (HMAs), used alone or in combination with other drugs, in the frontline, maintenance, relapsed/refractory, and peritransplant settings. Effective maintenance therapy has long been a goal for patients with AML in remission. Previous large, randomized clinical trials of maintenance with HMAs or other agents had not shown meaningful improvement in overall survival....
Source: Clinical Lymphoma, Myeloma and Leukemia - October 7, 2021 Category: Hematology Authors: Guillermo Garcia-Manero, Hartmut D öhner, Andrew H. Wei, Ignazia La Torre, Barry Skikne, CL Beach, Valeria Santini Source Type: research

Clinical and Sociodemographic Characteristics of Patients with Relapsed and/or Refractory Multiple Myeloma and their influence on Treatment in the Real-World Setting in Spain: the CharisMMa Study
Introduction: Treatment of relapsed and/or refractory multiple myeloma (RRMM) should be established based on multiple factors, including previous treatment and the sociodemographic/clinical characteristics of the patients. However, patients enrolled in randomized-controlled trials often do not mirror the scenario encountered in real-world practice, thus challenging therapeutic decisions in day-to-day practice.Patients and methods: This observational, cross-sectional, multicenter study aimed to investigate the sociodemographic and clinical characteristics of patients with RRMM treated in routine practice in Spain and their ...
Source: Clinical Lymphoma, Myeloma and Leukemia - October 7, 2021 Category: Hematology Authors: Enrique M. Ocio, Carmen Montes-Gais án, Gabriela Bustamante, Sebastián Garzón, Esther González, Ernesto Pérez, Maialen Sirvent, José María Arguiñano, Yolanda González, Rafael Ríos, Dunia de Miguel, Marta Grande, Alonso Fernández, Andrea Naves, Source Type: research

Prevalence and Clinical Outcome of FMS-like Tyrosine Kinase Mutations Amongst Patients with Core Binding Factor – Acute Myeloid Leukemia: Systematic Review and Meta-analysis
Two classes of mutation, namely, type-I and type-II mutations, work synergistically to develop acute myeloid leukemia (AML) in vivo. Type-I mutations occur in the genes (FLT3, WT1, KIT, RAS, etc) involved in signal transduction pathways which contribute to the growth and survival, whereas type-II mutations (RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA, NPM1 and CEBPA) act by blocking differentiation and/or enhancing self-renewal of leukemic cells.1 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 2, 2021 Category: Hematology Authors: Shyam Srinivasan, Shathish Kumar, Kalasekhar Vijayasekharan, Amit Kumar Agrawal Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2021 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2021 Category: Hematology Source Type: research

Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML after an antecedent hematologic disorder and therapy related AML
Therapy related acute myeloid leukemia (tAML) and secondary AML after an antecedent hematologic disorder (sAML-AHD) are often addressed together, blurring any clinical and prognostic differences. Among 516 AML patients, we compared characteristics and outcomes of 149 patients with “sAML” (sAML-AHD: 104, tAML: 45), uniformly and intensively treated during the last 2 decades at one center. Clinical outcomes of the whole “sAML” cohort were significantly inferior compared to de novo AML and in both intermediate and poor cytogenetic risk groups. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2021 Category: Hematology Authors: Chrysavgi Lalayanni, Eleni Gavriilaki, Anastasia Athanasiadou, Michael Iskas, Maria Papathanasiou, Anastasia Marvaki, Sotiria Mpesikli, Giorgos Papaioannou, Despina Mallouri, Ioannis Batsis, Apostolia Papalexandri, Ioanna Sakellari, Achilles Anagnostopoul Source Type: research

Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience
In the real-life setting, the combination of brentuximab vedotin and bendamustine was well tolerated and produced an ORR of 75%, CR 50% and a median PFS of 26 months. A significant proportion of heavily pretreated cHL patients may be cured with this approach. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 29, 2021 Category: Hematology Authors: Marina Moretti, Anna Marina Liberati, Luigi Rigacci, Benedetta Puccini, Alessandro Pulsoni, Guido Gini, Piero Galieni, Alberto Fabbri, Maria Cantonetti, Vincenzo Pavone, Silvia Bolis, Barbara Botto, Daniela Renzi, Lorenzo Falchi Tags: Original article Source Type: research

Outcomes of HTLV-1 Carriers with Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Matched Cohort Study
The human T-cell lymphotropic virus type 1 (HTLV-1) is associated with aggressive diseases, such as adult T-cell leukemia/lymphoma (ATLL). However, less is known on the impact of HTLV-1 infection in non-ATLL hematologic malignancies. We aimed to investigate if HTLV-1 carriers with diffuse large B-cell lymphoma (DLBCL) have worse survival outcomes than non-HTLV-1 carriers. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 29, 2021 Category: Hematology Authors: Bryan Valcarcel, Gustavo Sandival Ampuero, Gabriel de la Cruz-Ku, Daniel J Enriquez, Luis Malpica Source Type: research

Brentuximab-vedotin and bendamustine produce long-term clinical benefit in patients with refractory or relapsed classical Hodgkin lymphoma: a multicenter real-life experience
Patients with relapsed or refractory classical Hodgkin lymphoma (R/RcHL) have limited opportunities for a curative therapy. High-dose therapy followed by autologous stem cell transplantation (HDT-ASCT) produces cure rates of 50-60%. Patients relapsing after, or ineligible for HDT-ASCT have limited therapeutic options and long-term remission is uncommon. Furthermore, few patients are candidate to allogeneic stem cell transplantation (AlSCT), a potentially curative approach. The combination of brentuximab-vedotin and bendamustine (BVB) is a promising treatment for patients with R/RcHL, regardless of SCT eligibility. (Source:...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 29, 2021 Category: Hematology Authors: Marina Moretti, Anna Marina Liberati, Luigi Rigacci, Benedetta Puccini, Alessandro Pulsoni, Guido Gini, Piero Galieni, Alberto Fabbri, Maria Cantonetti, Vincenzo Pavone, Silvia Bolis, Barbara Botto, Daniela Renzi, Lorenzo Falchi Tags: Original article Source Type: research

Clinical characteristics, prognosis, and treatment strategies of TP53 mutations in myelodysplastic syndromes
TP53 gene mutations are common in myelodysplastic syndromes (MDS). Previous studies have reported their detrimental effects on patient survival. However, current treatment strategies mainly based on hypomethylating agent therapy(HMA) and hematopoietic stem cell transplantation(HSCT) still leave a lot to be desired. And there is also a lack of studies on large sample with a view to the refinement of specific characteristics and disease progression. So we performed a meta-analysis including 20 studies compromising 5067 patients to assess the prognostic impact and clinical characteristics of TP53 mutations in MDS patients. (S...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 25, 2021 Category: Hematology Authors: Kun Fang, Jiaqian Qi, Meng Zhou, Ziyan Zhang, Yue Han Source Type: research

Validation of AML-Score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia
: The AML-Score is a web-based tool that was designed to predict the risk of complete remission and early mortality in older patients with acute myeloid leukemia being treated with traditional induction chemotherapy. This retrospective study of 40 patients assesses the validity of the AML-Score in a cohort of older patients with secondary AML who received induction chemotherapy with the newer agent, CPX-351. Results of the study show that the AML-Score trends in the correct direction for predicting CR and EM in this patient population and may facilitate oncologist decision making when considering treatment with CPX-351. (S...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 24, 2021 Category: Hematology Authors: Abigail M. Schmucker, Benjamin E. Leiby, Lindsay Wilde Source Type: research

The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma
This study examined the safety and efficacy of palliative RT given in the setting of concurrent dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 24, 2021 Category: Hematology Authors: Anthony D. Nehlsen, Kunal K. Sindhu, Erin Moshier, Joshua Richter, Shambavi Richard, Ajai Chari, Larysa Sanchez, Samir Parekh, Hearn Jay Cho, Sundar Jagannath, Kavita Dharmarajan Source Type: research

Bing-Neel syndrome: update on the diagnosis and treatment
Waldenstrom macroglobulinemia (WM) is a rare lymphoid neoplasm characterized by unregulated growth of immunoglobulin M (IgM)-producing monoclonal lymphoplasmacytic lymphocytes (LPLs) in the bone marrow. It constitutes only 1-2% of hematologic malignancies and usually affects males between 50 and 70 years1. The manifestations of WM are usually related to IgM paraproteinemia and include hyperviscosity, hemolytic anemia, and/or peripheral neuropathy. The lymphoplasmacytic proliferation can involve extramedullary tissue in 20% of cases of WM2. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 24, 2021 Category: Hematology Authors: Abdelrahman Nanah, Samer Al Hadidi Tags: Review article Source Type: research

Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
: Loncastuximab tesirine has shown antitumor activity with an acceptable toxicity profile in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who were relapsed or refractory after ≥2 prior therapies, including activity in patients with high-risk disease characteristics. This analysis examined health-related quality of life (HRQoL), symptoms, and tolerability in patients receiving loncastuximab tesirine for relapsed or refractory DLBCL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2021 Category: Hematology Authors: Alexander Spira, Xiaolei Zhou, Lei Chen, Ari Gnanasakthy, Luqiang Wang, David Ungar, Rafael Curiel, Laura Liao, John Radford, Brad Kahl Source Type: research

BTK inhibitors combined with chemoimmunotherapy in CLL – the best of both worlds?
Chemoimmunotherapy (CIT) remains a standard-of-care in many regions for first line (1L) therapy of CLL. In fit patients, fludarabine, cyclophosphamide and rituximab (FCR) has the advantage of achieving undetectable measurable residual disease (MRD) with time-limited treatment and prolonged treatment-free remissions with a plateau on the PFS curve, but has several limitations, most notably the inferior PFS and survival outcomes for patients with unmutated IGHV compared to ibrutinib  + rituximab seen in the E1912 study and a risk for long-term toxicities such as therapy-related myeloid neoplasms. (Source: Clinical Lympho...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2021 Category: Hematology Authors: Dr. Philip A. Thompson Source Type: research

Refractory DLBCL: Challenges and Treatment
Despite a greater understanding of pathologic factors that increase the chance for treatment failure, initial therapy of diffuse large B cell lymphoma (DLBCL) has not evolved from R/CHOP. Although it was anticipated that the genetic underpinnings of the cell or origin would dramatically change treatment, thus far, this has not been realized. Similarly, contrary to the situation with Hodgkin lymphoma, meaningful early treatment response assessment with PET CT has yet to be established in DLBCL. Nevertheless, there is tremendous enthusiasm that circulating tumor DNA, possibly in combination with PET CT may facilitate earlier...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2021 Category: Hematology Authors: Mendel Goldfinger, Dennis L. Cooper Source Type: research

FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia of adults, with a five-year survival that remains poor (approximately 25%). Knowledge and understanding of AML genomics have expanded tremendously over the past decade and are now included in AML prognostication and treatment decisions. FMS-like tyrosine kinase 3 (FLT3) is a Class III receptor tyrosine kinase (RTK) expressed primarily in the cell membranes of early hematopoietic progenitor cells, found in 28% of all patients with AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 16, 2021 Category: Hematology Authors: Elli D. Novatcheva, Yasmine Anouty, Ila Saunders, James K. Mangan, Aaron M. Goodman Tags: Review Article Source Type: research

FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia of adults, with a five-year survival that remains poor (approximately 25%). Knowledge and understanding of AML genomics have expanded tremendously over the past decade and are now included in AML prognostication and treatment decisions. FMS-like tyrosine kinase 3 (FLT3) is a Class III receptor tyrosine kinase (RTK) expressed primarily in the cell membranes of early hematopoietic progenitor cells, found in 28% of all patients with AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 16, 2021 Category: Hematology Authors: Elli D. Novatcheva, Yasmine Anouty, Ila Saunders, James K. Mangan, Aaron M. Goodman Tags: Review Article Source Type: research

The Real ‐World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 14, 2021 Category: Hematology Authors: Seval Akpinar, Mehmet Hilmi Dogu, Serhat Celik, Omer Ekinci, Ipek Yonal Hindilerden, Mehmet Sinan Dal, Eren Arslan Davulcu, Atakan Tekinalp, Fehmi Hindilerden, Busra Gokce Ozcan, Tuba Hacibekiroglu, Mehmet Ali Erkurt, Metin Bagci, Sinem Namdaroglu, Gulten Tags: Original Studies Source Type: research

Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience
Though the available number and efficacy of novel agents for multiple myeloma (MM) have grown in recent years, it remains an incurable disease with relapse inevitable in nearly all patients. Autologous stem cell transplantation (ASCT) after induction chemotherapy remains the standard of care for transplant-eligible patients, with randomized studies demonstrating median progression-free survival (PFS) greater than 4 years1. Options at relapse have similarly continued to improve with numerous agents and combinations now available; in some salvage settings treatment can yield a PFS in excess of 3 years2. (Source: Clinical Lym...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 14, 2021 Category: Hematology Authors: Derek Galligan, Staci Williamson, Jessie Myers, Rebecca Silbermann, Eva Medvedova, Sarah Nagle, Levanto Schachter, Andy Chen, Emma Scott, Richard Maziarz Source Type: research

The real world experience with single agent ibrutinib in relapsed/refractory cll
Chronic lymphocytic leukemia (CLL) is characterized by progressive accumulation of mature-appearing monoclonal B lymphocytes and is the most prevalent form of leukemia in the Western world.1 Although chemoimmunotherapy is still a reasonable treatment option for standard-risk/fit patients, the management of high-risk patients presenting with del17p/p53mut or unmutated IGHV (uIGHV) has been an unmet medical need in achieving long-term survival. The emergence of novel agents targeting the B-cell receptor pathway (ibrutinib, acalubritinib, idealisib) and BCL-2 (venetoclax) has significantly changed the therapeutic landscape of...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 14, 2021 Category: Hematology Authors: Seval Akpinar, Mehmet Hilmi Dogu, Serhat Celik, Omer Ekinci, Ipek Yonal Hindilerden, Mehmet Sinan Dal, Eren Arslan Davulcu, Atakan Tekinalp, Fehmi Hindilerden, Busra Gokce Ozcan, Tuba Hacibekiroglu, Mehmet Ali Erkurt, Metin Bagci, Sinem Namdaroglu, Gulten Source Type: research

Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype
We reported 24 CBF-AML patients with complex karyotype. Our data suggested to reconsider the good prognosis historically associated with CBF AML despite of karyotype. The place of ASCT should be discussed in the strategy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 11, 2021 Category: Hematology Authors: Clemence Marcault, Nicolas Boissel, Claudia Haferlach, Michael Loschi, Sophie Raynaud, Thomas Cluzeau Source Type: research

Improvements in Health-Related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries,1 and accounts for approximately one-third of new leukemia cases in the United States each year.2 It is seen mainly in older adults, with an average age at diagnosis of 70 years.3 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 11, 2021 Category: Hematology Authors: Alexey V. Danilov, Habte A. Yimer, Michael A. Boxer, John M. Burke, Sunil Babu, Jia Li, Yong Mun, Peter C. Trask, Anthony S. Masaquel, Jeff P. Sharman Tags: Original article Source Type: research

Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia with Complex Karyotype.
CBF AML with recurrent genetic abnormalities inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/ CBFB-MYH11 are usually prognostically favorable but heterogeneous group and additional abnormalities change their prognosis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 11, 2021 Category: Hematology Authors: Clemence Marcault, Nicolas Boissel, Claudia Haferlach, Michael Loschi, Sophie Raynaud, Thomas Cluzeau Source Type: research

Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients ’ Perspectives on Treatment
This study assessed the impact of IV/SC HMA on MDS patients, and their experience of, challenges with, and views about oral MDS treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 11, 2021 Category: Hematology Authors: Amer M. Zeidan, Sayeli Jayade, Jordana Schmier, Marc Botteman, Audrey Hassan, Desiree Ruiters, Kala Hill, Namita Joshi Source Type: research

Impact of radiation therapy after high dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with relapsed/refractory lymphomas: a single center experience
There is a significant improvement over the last two decades in the primary treatment of diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma (HL) lymphoma. DLBCL and HL patients with relapsed disease or failing to achieve remission can still be salvage with high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT). 1,2 Patients with relapsed/refractory HL can have a 5-year progression-free survival (PFS) of 50% - 60% after salvage chemotherapy and HDC auto-SCT. 3,4 There are many factors reported to have an adverse impact on long-term survival in patients who underwent HDC auto-SCT for relapse...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 10, 2021 Category: Hematology Authors: Asif Husain Osmani, Yasser Khafaga, M Shahzad Rauf, Irfan Maghfoor, Saad Akhtar Source Type: research

Treatment Bridging with a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma
Cancer treatment, particularly that of multiple myeloma (MM), has drastically evolved over the past decade as we better understood the tumor microenvironment and began utilizing therapies to target tumor cells1,2. This has been accomplished with monoclonal and bispecific antibodies as well as chimeric antigen receptor (CAR)-T cell therapy3-5. However, management of patients who have failed approved agents and have rapidly progressive disease with cytopenias continues to be challenging. Many patients hope to qualify for a clinical trial option, particularly when their disease becomes triple-class or penta-refractory with a ...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 10, 2021 Category: Hematology Authors: Tarek H. Mouhieddine, Julia Hieulle, Erin Moshier, Shambavi Richard, Joshua Richter, Hearn Jay Cho, Samir Parekh, Bart Barlogie, Ajai Chari, Sundar Jagannath, Deepu Madduri Source Type: research

‘Le Roi est mort, vive le Roi’: new roles of radiotherapy in the treatment of lymphomas in combination with immunotherapy.
immunotherapy (IT), including checkpoint inhibitors (CIs) and Chimeric Antigen Receptor T cell therapy (CAR-T) revolutionized the treatment of relapsing or refractory (r/r) lymphoma. Several preliminary experiences evaluated concomitant administration of radiotherapy and IT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 10, 2021 Category: Hematology Authors: Andrea Emanuele Guerini, Andrea Riccardo Filippi, Alessandra Tucci, Gabriele Simontacchi, Alessandro Re, Annamaria Guaineri, Vittorio Morelli, Paolo Borghetti, Luca Triggiani, Ludovica Pegurri, Sara Pedretti, Giulia Volpi, Luigi Spiazzi, Stefano Maria Mag Source Type: research

Epidemiology of Food Insecurity in a Nationally Representative Sample of Lymphoma Patients
In 2020, the United States had approximately 85,000 new diagnoses of Hodgkin and Non-Hodgkin lymphoma. Food insecurity is both a direct and indirect detriment to health outcomes. The rate and risk factors for food insecurity among lymphoma patients are unknown, as the unemployment rate soars far above pre-COVID19 pandemic levels further heightening the economic stresses of a lymphoma diagnosis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 10, 2021 Category: Hematology Authors: Taral Jella, Thomas B. Cwalina, Mehdi Hamadani Source Type: research

Acute myeloid leukemia patients requiring two cycles of intensive induction for attainment of remission experience inferior survival compared with patients requiring a single course of induction chemotherapy
Achievement of initial remission remains the most important clinical factor predicting long term survival in acute myeloid leukemia (AML) patients treated with intensive chemotherapy. Yet, whether the patient subset in need of a second cycle of intensive induction chemotherapy to reach remission experiences inferior outcomes compared to patients reaching remission after a single cycle of therapy, remains uncertain. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 8, 2021 Category: Hematology Authors: Gal Sharvit, Gabriel Heering, Maya Zlotnik, Drorit Merkel, Arnon Nagler, Abraham Avigdor, Avichai Shimoni, Jonathan Canaani Source Type: research

Harnessing Apoptosis in AML
The treatment landscape for AML has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in AML continues to be explo...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 3, 2021 Category: Hematology Authors: Kapil Saxena, Courtney DiNardo, Naval Daver, Marina Konopleva Source Type: research

Diabetes and the prognosis in patients with non-Hodgkin lymphoma: a meta-analysis of cohort studies
Consensus lacks regarding the association between diabetes mellitus (DM) and the prognosis of patients with non-Hodgkin lymphoma (NHL). We aimed to systematically evaluate the above association, as well as the potential influence of metformin use in a meta-analysis of cohort studies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 31, 2021 Category: Hematology Authors: Zhen Han, Hong Xu, Meiqing Zhao, Fangjing Jing, Hongwei Xue, Shuxin Xiao Source Type: research

Impact of cell of origin on outcomes after autologous hematopoietic cell transplant in diffuse large B-cell lymphoma
Germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) at diagnosis is associated with superior long-term outcomes compared to non-GCB-DLBCL in patients treated with conventional chemo-immunotherapy. Whether cell of origin (COO) by Hans algorithm retains its prognostic significance in patients with (R/R) relapsed/refractory DLBCL undergoing autologous hematopoietic cell transplant (auto-HCT) is not well established. Three hundred and fifty-seven patients underwent auto-HCT between 2005 and 2018. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 31, 2021 Category: Hematology Authors: Madiha Iqbal, Yennifer Gil Castano, Jonas Paludo, Allison Rosenthal, Zhuo Li, Manuel Beltran, Muhamad Alhaj Moustafa, David Inwards, Luis Porrata, Ivana Micallef, Jose C. Villasboas Bisneto, Patrick Johnston, Stephen M. Ansell, Craig Reeder, Hemant Murthy Source Type: research

Association of -308g/a, -238g/a tnf- α polymorphisms with multiple myeloma risk and survival: a systematic review and meta-analysis.
Tumor necrosis factor alpha (TNF- α) is a cytokine with a key role in proinflammation and multiple diseases, including cancer. The gene encoding TNF-α is located within a highly polymorphic region on chromosome 6p21.3; two polymorphisms -308G/A (rs1800629) and -238G/A (rs361525) have been associated with occurrence of human diseas es. There is a debate in recent meta-analyses that reached discrepant conclusions regarding the potential role of TNF-α polymorphisms in multiple myeloma (MM) risk. The aim of this systematic review and meta-analysis is to investigate the association between the aforementioned t...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 30, 2021 Category: Hematology Authors: Christina M. Alymatiri, Georgia T. Gkegka, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos, Theodoros N. Sergentanis, Theodora Psaltopoulou Source Type: research

Favorable long-term outcomes with autologous stem cell transplantation for high-risk multiple myeloma patients with a positive result on 18F-FDG PET/CT at baseline
The clinical significance of image evaluation for multiple myeloma (MM) is increasing with the use of novel imaging techniques. Osteolytic lesions detected by computed tomography (CT) and focal lesions (FL) detected by positron emission tomography/CT (PET/CT) or magnetic resonance imaging (MRI) at the initial workup are critical events requiring treatment initiation.1. Additionally, it is widely assumed that residual lesions on functional imaging techniques, such as MRI or PET/CT, during the follow-up period after treatment are associated with poor prognosis2. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 30, 2021 Category: Hematology Authors: Hee Jeong Cho, Dong Won Baek, Ju-Hyung Kim, Jungmin Lee, Yu Kyung Chung, Sung-Hoon Jung, Ga-young Song, Seo-Yeon Ahn, Jae Sook Ahn, Deok-Hwan Yang, Je-Jung Lee, Hyeong-Joon Kim, Chae Moon Hong, Shin Young Jeong, Jung-Joon Min, Sang-Kyun Sohn, Joon Ho Moon Source Type: research

Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry
In multiple myeloma (MM), the t (11;14) (q13;q32) translocation [t (11;14)] is a common cytogenetic abnormality and the most frequently occurring translocation found in 15% to 24% of patients.1-4 Although t (11;14) is classified as standard risk according to International Myeloma Working Group guidelines,5 the prognostic effect of t (11;14) in MM has been evaluated in several studies with varying conclusions.2, 4, 6-11 Historically, the presence of t (11;14) was associated with favorable outcomes or limited impact. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 29, 2021 Category: Hematology Authors: Cristina J. Gasparetto, Sundar Jagannath, Robert M. Rifkin, Brian G.M. Durie, Mohit Narang, Howard R. Terebelo, Kathleen Toomey, James W. Hardin, Lynne Wagner, Sikander Ailawadhi, James L. Omel, Shankar Srinivasan, Mazaher Dhalla, Donna Catamero, Amani Ki Source Type: research

The impact of Atrial Fibrillation on hospitalization outcomes for patients with Chronic Lymphocytic Leukemia using the National Inpatient Sample Database
Background: The incidence of atrial fibrillation (AF) in patients with chronic lymphocytic leukemia (CLL) has been on the rise. However, the excess burden added by AF to the morbidity and mortality of CLL patients especially in the hospitalized setting is undetermined.Methods: The National Inpatient Sample (NIS) database was accessed to gather data of hospitalized CLL patients with AF from 2009 to 2018. Propensity-score matching (PSM) and logistic regression model were performed to control for baseline patient factors to match 7265 CLL patient admissions with AF and 7265 CLL patient admissions without AF. (Source: Clinical...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 28, 2021 Category: Hematology Authors: Mohammad Ammad Ud Din, Samarthkumar Thakkar, Harsh Patel, Hassan Saaed, Syed Ather Hussain, Hania Liaqat, Aneeqa Zafar, Sourbha S. Dani, Sarju Ganatra, Faiz Anwer Source Type: research

Single-dose rasburicase might be adequate to overcome tumor lysis syndrome in hematological malignancies
Introduction: Tumor lysis syndrome (TLS) is a commonly observed oncological emergency that requires prompt diagnosis and treatment. Rasburicase is a recombinant urate oxidase endorsed in TLS for the treatment of hyperuricemia. The effect of single-dose 7.5 mg rasburicase at longer follow-ups was not widely investigated.Patients and Methods: Eighty-two patients included in the study with clinical TLS and laboratory TLS. The primary endpoint was the normalization of uric acid ( (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 28, 2021 Category: Hematology Authors: Samet Yaman, Semih Ba şcı, Gökhan Turan, Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Mehmet Sinan Dal, Merih Kızıl Çakar, Fevzi Altuntaş Source Type: research

Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study
We assessed the efficacy and safety of rituximab and its biosimilar, CT-P10, in treatment-na ïve low-tumor-burden follicular lymphoma patients, with a median follow-up of 29.2 months. Data from the trial show that the efficacy and safety of rituximab and CT-P10 were similar, including after a single switch from rituximab to CT-P10. These data support the therapeutic similarity of rituximab and CT-P10. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 27, 2021 Category: Hematology Authors: Larry W. Kwak, Juan-Manuel Sancho, Seok-Goo Cho, Hideyuki Nakazawa, Junji Suzumiya, Gayane Tumyan, Jin Seok Kim, Tobias Menne, Jos é Mariz, Nikolai Ilyin, Wojciech Jurczak, Aurelio Lopez Martinez, Olga Samoilova, Edvard Zhavrid, Eduardo Yañez Ruiz, Mare Tags: Original article Source Type: research

Follicular Lymphoma: Refining Prognostic Models and Impact of Pod-24 in Clinical Outcomes
Follicular lymphoma (FL) is the most common indolent lymphoma, accounting for 20%-25% of all non –Hodgkin's lymphomas (NHLs). It is a malignancy with variable biologic presentation and heterogeneous clinical outcomes. Several models incorporating clinical laboratory variables and molecular biomarkers are able to predict its prognosis, allowing to stratify patients into different risk groups. However, these prognostic scores should not be used to indicate first-line treatment or risk-adapted therapeutic recommendations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 27, 2021 Category: Hematology Authors: Daniel Silva Nogueira, Lu ís Alberto de Pádua Covas Lage, Hebert Fabrício Culler, Juliana Pereira Tags: Review Article Source Type: research

Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumour-Burden Follicular Lymphoma: Final Results of a Randomised Phase 3 Study
Abbreviations: ADA  = antidrug antibody; CI = confidence interval; FL = follicular lymphoma; GELF = Groupe D'Etude des Lymphomes Folliculaires; IRR = infusion-related reaction; ITT = intention-to-treat; IV = intravenously; LTBFL = low-tumour-burden follicular lymphoma; MP1 = mainten ance period 1; MP2 = maintenance period 2; NCCN = National Comprehensive Cancer Network; ORR = overall response rate; OS = overall survival; PFS = progression-free survival; RA = rheumatoid arthritis; TEAE = treatment-emergent adverse event; TESAE = treatment-emergent serious a...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 27, 2021 Category: Hematology Authors: Larry W. Kwak, Juan-Manuel Sancho, Seok-Goo Cho, Hideyuki Nakazawa, Junji Suzumiya, Gayane Tumyan, Jin Seok Kim, Tobias Menne, Jos é Mariz, Nikolai Ilyin, Wojciech Jurczak, Aurelio Lopez Martinez, Olga Samoilova, Edvard Zhavrid, Eduardo Yañez Ruiz, Mare Source Type: research